A joint professional advisory emphasizes adequate high-quality food and protein, prevention of very low energy or micronutrient intake, and risk-based monitoring. A safe target cannot be derived from body weight alone; age, kidney function, treatment tolerance and the clinical plan matter.
On 1 December 2025 the World Health Organization issued its first global guideline on GLP-1 therapy for obesity in adults. It conditionally recommends liraglutide, semaglutide and tirzepatide for long-term treatment of adults with obesity (BMI 30 or higher), excluding pregnant women. A second, also conditional recommendation, based on low-certainty evidence, states that people on this treatment may be offered a structured intensive programme focused on diet and physical activity. Even for WHO, the medicine is therefore not a stand-alone solution.
More protein alone is unlikely to preserve muscle without resistance or strength exercise. Training must be adapted to baseline function, joints, symptoms and access; a generic weekly target is a goal to individualize, not a condition for medication safety.
Persistent vomiting, inability to eat or drink adequately, rapid functional decline or signs of dehydration need clinical review. Supplements such as creatine do not replace nutrition, training or medical monitoring.